The number of EVs expressing CD82 can forecast cancer prognosisby disclosing the potential for metastasis; fewer CD82+ EVs can point to an increased chance of metastasis in cancers, servingas a useful predictor of outcomes. This evidence concerns the gene CD82 and cancer.